Brought to you by 
CR Bard buys SenoRx for $193mm in cash
06 May 2010
Executive Summary
CR Bard Inc. (vascular, urology, oncology, and surgical specialty products) is acquiring all the outstanding shares of publicly traded SenoRx Inc. (breast cancer devices) for $11 each (an 11% premium), or a total of $193mm.
Deal Industry
- Medical Devices
-
Medical Devices
- Diagnostic Equipment & Supplies
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Diagnostic Imaging Equipment & Supplies
- MRI, NMR
- X-ray
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CR Bard buys SenoRx for $193mm in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice